PLA2R1 and membranous glomerulonephritis: These results suggest that the disappearance of anti-PLA2R antibodies after RTX treatment correlates with clinical remission, indicating that immunological remission may be an indicator of renal survival after treatment with RTX for patients with membranous nephropathy and renal dysfunction.